Literature DB >> 19493612

Activin is a potent growth suppressor of epithelial ovarian cancer cells.

Anassuya Ramachandran1, Elaine S Marshall, Donald R Love, Bruce C Baguley, Andrew N Shelling.   

Abstract

Although activin is a major cytokine produced by the ovary, its role in epithelial ovarian cancer is poorly defined. Here, we demonstrate a novel role for activin as a growth inhibitor of some (8/16) epithelial ovarian cancer cell lines. Unresponsive cell lines displayed transcriptional downregulation of the activin receptors ACTRIIA and ACTRIB, suggesting resistance to activin signalling. In response to activin, growth inhibited cell lines demonstrated activation of the canonical SMAD2/3/4, transcriptional induction of the CDK inhibitor p15INK4B, suppression of C-MYC levels and a G1 phase cell cycle arrest. Thus, activin is a potent inhibitor of proliferation of some epithelial ovarian cancer cell lines and its role in the pathogenesis of this disease needs to be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493612     DOI: 10.1016/j.canlet.2009.05.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling.

Authors:  Matthew Dean; David A Davis; Joanna E Burdette
Journal:  Cancer Lett       Date:  2017-01-20       Impact factor: 8.679

2.  HBx interacted with Smad4 to deprive activin a growth inhibition function in hepatocyte HL7702 on CRM1 manner.

Authors:  Ying Shi; Haipeng Zhang; Zhu Han; Xuguang Mi; Wenyan Zhang; Mingyu Lv
Journal:  Tumour Biol       Date:  2015-10-08

3.  Effect of Dendrobium officinale Extraction on Gastric Carcinogenesis in Rats.

Authors:  Yi Zhao; Yan Liu; Xi-Ming Lan; Guo-Liang Xu; You-Zhi Sun; Fei Li; Hong-Ning Liu
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-29       Impact factor: 2.629

4.  Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis.

Authors:  Jian Sun; Xuan Liu; Hong Gao; Long Zhang; Qing Ji; Ziyuan Wang; Lihong Zhou; Yan Wang; Hua Sui; Zhongze Fan; Qi Li
Journal:  Oncotarget       Date:  2017-02-14

5.  Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.

Authors:  Yosuke Togashi; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A de Velasco; Yoshihiko Fujita; Yasuo Kodera; Kazuko Sakai; Shuta Tomida; Masayuki Kitano; Akihiko Ito; Masatoshi Kudo; Kazuto Nishio
Journal:  Mol Cancer       Date:  2014-05-27       Impact factor: 27.401

6.  Germline mutations of inhibins in early-onset ovarian epithelial tumors.

Authors:  Isabelle Tournier; Régine Marlin; Kelly Walton; Françoise Charbonnier; Sophie Coutant; Jean-Christophe Théry; Camille Charbonnier; Cailyn Spurrell; Myriam Vezain; Lorena Ippolito; Gaëlle Bougeard; Horace Roman; Julie Tinat; Jean-Christophe Sabourin; Dominique Stoppa-Lyonnet; Olivier Caron; Brigitte Bressac-de Paillerets; Dominique Vaur; Mary-Claire King; Craig Harrison; Thierry Frebourg
Journal:  Hum Mutat       Date:  2013-12-27       Impact factor: 4.878

7.  Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.

Authors:  Xiaoting Li; Zongyuan Yang; Sen Xu; Zhengzheng Wang; Ping Jin; Xin Yang; Zeyu Zhang; Ya Wang; Xiao Wei; Tian Fang; Qinglei Gao
Journal:  Dis Markers       Date:  2019-11-11       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.